LAS 34475

Drug Profile

LAS 34475

Latest Information Update: 24 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Almirall S.A.
  • Class Anti-inflammatories; Non-opioid analgesics; Oxazoles; Small molecules
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoarthritis; Pain

Most Recent Events

  • 20 Jun 2003 Phase-II/III clinical trials in Osteoarthritis in Spain (PO)
  • 20 Jun 2003 Phase-II/III clinical trials in Osteoarthritis in USA (PO)
  • 20 Jun 2003 Data presented at the 4th Annual European Congress of Rheumatology (EULAR-2003) have been added to the pharmacokinetics, adverse events and Rheumatic disease pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top